LV13630B - Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone - Google Patents
Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone Download PDFInfo
- Publication number
- LV13630B LV13630B LVP-06-45A LV060045A LV13630B LV 13630 B LV13630 B LV 13630B LV 060045 A LV060045 A LV 060045A LV 13630 B LV13630 B LV 13630B
- Authority
- LV
- Latvia
- Prior art keywords
- pyrrolidinone
- phenyl
- compound
- carbamoylmethyl
- phenotropil
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract description 10
- 238000002360 preparation method Methods 0.000 title abstract description 9
- LYONXVJRBWWGQO-JTQLQIEISA-N 2-[(4r)-2-oxo-4-phenylpyrrolidin-1-yl]acetamide Chemical compound C1C(=O)N(CC(=O)N)C[C@H]1C1=CC=CC=C1 LYONXVJRBWWGQO-JTQLQIEISA-N 0.000 title 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229910021529 ammonia Inorganic materials 0.000 claims abstract description 6
- 238000007126 N-alkylation reaction Methods 0.000 claims abstract description 5
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 20
- 230000006742 locomotor activity Effects 0.000 claims description 4
- 230000021235 carbamoylation Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000002276 neurotropic effect Effects 0.000 claims description 2
- JMVIVASFFKKFQK-UHFFFAOYSA-N 1-phenylpyrrolidin-2-one Chemical compound O=C1CCCN1C1=CC=CC=C1 JMVIVASFFKKFQK-UHFFFAOYSA-N 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 206010021118 Hypotonia Diseases 0.000 claims 1
- 230000036592 analgesia Effects 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 150000008282 halocarbons Chemical group 0.000 claims 1
- 230000036640 muscle relaxation Effects 0.000 claims 1
- LYONXVJRBWWGQO-UHFFFAOYSA-N 2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide Chemical compound C1C(=O)N(CC(=O)N)CC1C1=CC=CC=C1 LYONXVJRBWWGQO-UHFFFAOYSA-N 0.000 abstract description 9
- 230000000144 pharmacologic effect Effects 0.000 abstract description 5
- GLCIFTVZMWHJBE-LBPRGKRZSA-N ethyl 2-[(4r)-2-oxo-4-phenylpyrrolidin-1-yl]acetate Chemical compound C1C(=O)N(CC(=O)OCC)C[C@H]1C1=CC=CC=C1 GLCIFTVZMWHJBE-LBPRGKRZSA-N 0.000 abstract description 3
- HOJZEMQCQRPLQQ-VIFPVBQESA-N (4r)-4-phenylpyrrolidin-2-one Chemical compound C1NC(=O)C[C@@H]1C1=CC=CC=C1 HOJZEMQCQRPLQQ-VIFPVBQESA-N 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000000202 analgesic effect Effects 0.000 description 6
- 239000003158 myorelaxant agent Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000001430 anti-depressive effect Effects 0.000 description 5
- 239000000935 antidepressant agent Substances 0.000 description 5
- 229940005513 antidepressants Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 102220079670 rs759826252 Human genes 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical class O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- JGONJCYCUZRGQF-UHFFFAOYSA-N 2-(3-phenylpyrrolidin-1-yl)acetamide Chemical compound C1N(CC(=O)N)CCC1C1=CC=CC=C1 JGONJCYCUZRGQF-UHFFFAOYSA-N 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- -1 analgesic Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- DAFOCGYVTAOKAJ-UHFFFAOYSA-N phenibut Chemical compound OC(=O)CC(CN)C1=CC=CC=C1 DAFOCGYVTAOKAJ-UHFFFAOYSA-N 0.000 description 1
- 229960004122 phenibut Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002582 psychostimulating effect Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 150000003953 γ-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Priority Applications (22)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LVP-06-45A LV13630B (en) | 2006-03-16 | 2006-03-16 | Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone |
| SI200730253T SI2013166T1 (sl) | 2006-03-16 | 2007-03-15 | N-karbamoilmetil-4(r)-fenil-2-pirolidinon, postopek za njegovo pripravo in farmacevtska uporaba |
| PL07726915T PL2013166T3 (pl) | 2006-03-16 | 2007-03-15 | N-karbamoilometylo-4(R)-fenylo-2-pirolidynon, sposób jego wytwarzania i zastosowanie farmaceutyczne |
| AT07726915T ATE460396T1 (de) | 2006-03-16 | 2007-03-15 | N-carbamoylmethyl-4-(r)-phenyl-2-pyrrolidinon, verfahren zu dessen herstellung und pharmazeutische verwendung |
| ES07726915T ES2342024T3 (es) | 2006-03-16 | 2007-03-15 | N-carbamoilmetil-4(r)-fenil-2-pirrolidinona, su procedimiento de prepaacion y uso farmaceutico. |
| CA2647206A CA2647206C (en) | 2006-03-16 | 2007-03-15 | N-carbamoylmethyl-4-(r)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use |
| PT07726915T PT2013166E (pt) | 2006-03-16 | 2007-03-15 | N-carbamoilmetilo-4(r)fenilo-2-pirrolidinona, processos de sua preparação e utilização farmacêutica |
| EP07726915A EP2013166B1 (en) | 2006-03-16 | 2007-03-15 | N-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use |
| DK07726915.7T DK2013166T3 (da) | 2006-03-16 | 2007-03-15 | N-carbamoylmethyl-4(R)-phenyl-2-pyrrolidon, fremgangsmåde til fremstilling heraf og farmaceutisk anvendelse |
| PCT/EP2007/052424 WO2007104780A2 (en) | 2006-03-16 | 2007-03-15 | N- carbamoylmethyl- 4- (r) -phenyl-2-pyrr0lidin0ne, method of its preparation and pharmaceutical use |
| UAA200812099A UA96440C2 (ru) | 2006-03-16 | 2007-03-15 | Способ получения и применения фармакологически активного n-карбамоилметил-4-(r)-фенил-2-пирролидинона |
| MEP-2009-293A ME01192B (me) | 2006-03-16 | 2007-03-15 | Metod pripreme i upotreba farmakološki aktivnog n-karbamoilmetil-4(r)-fenil-2-pirolidinona |
| DE602007005244T DE602007005244D1 (de) | 2006-03-16 | 2007-03-15 | N-carbamoylmethyl-4-(r)-phenyl-2-pyrrolidinon, verfahren zu dessen herstellung und pharmazeutische verwendung |
| HRP20090524AA HRP20090524C1 (hr) | 2006-03-16 | 2007-03-15 | Metoda priprave i upotreba farmakološki aktivnog n-karbamoilmetil-4(r)-fenil-2-pirolidinona |
| GEAP200710934A GEP20104915B (en) | 2006-03-16 | 2007-03-15 | N-carbamoylmethyl-4-(r) – phenyl-2-pyrr0lidin0ne, method of its preparation and pharmaceutical use |
| EA200801978A EA014668B1 (ru) | 2006-03-16 | 2007-03-15 | Способ получения и применения фармакологически активного n-карбамоилметил-4(r)-фенил-2-пирролидинона |
| CNA2007800177832A CN101448786A (zh) | 2006-03-16 | 2007-03-15 | N-氨基甲酰甲基-4(r)-苯基-2-吡咯烷酮的制备方法及药物用途 |
| US12/226,332 US9102615B2 (en) | 2006-03-16 | 2007-03-15 | N-Carbamoylmethy1-4-(R)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use |
| EEP200800063A EE05536B1 (et) | 2006-03-16 | 2007-03-15 | N-karbamoüülmetüül-4-(R)-fenüül-2-pürrolidinoon, selle valmistamise meetod ja farmatseutiline kasutamine |
| LT2008075A LT5589B (lt) | 2006-03-16 | 2008-09-22 | N-karbamoilmetil-4-(r)-fenil-2-pirolidinonas, jo gavimo būdas ir farmacinis panaudojimas |
| CY20101100506T CY1110170T1 (el) | 2006-03-16 | 2010-06-08 | Ν-καρβαμοϋλμεθυλ-4(-r)-φαινυλ-2-πυρρολιδινονη, μεθοδος παρασκευης της και φαρμακευτικη χρηση αυτης |
| US14/688,633 US9382203B2 (en) | 2006-03-16 | 2015-04-16 | N-carbamoylmethyl-4-(R)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LVP-06-45A LV13630B (en) | 2006-03-16 | 2006-03-16 | Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LV13630B true LV13630B (en) | 2007-12-20 |
Family
ID=38461010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-06-45A LV13630B (en) | 2006-03-16 | 2006-03-16 | Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9102615B2 (da) |
| EP (1) | EP2013166B1 (da) |
| CN (1) | CN101448786A (da) |
| AT (1) | ATE460396T1 (da) |
| CA (1) | CA2647206C (da) |
| CY (1) | CY1110170T1 (da) |
| DE (1) | DE602007005244D1 (da) |
| DK (1) | DK2013166T3 (da) |
| EA (1) | EA014668B1 (da) |
| EE (1) | EE05536B1 (da) |
| ES (1) | ES2342024T3 (da) |
| GE (1) | GEP20104915B (da) |
| HR (1) | HRP20090524C1 (da) |
| LT (1) | LT5589B (da) |
| LV (1) | LV13630B (da) |
| ME (1) | ME01192B (da) |
| PL (1) | PL2013166T3 (da) |
| PT (1) | PT2013166E (da) |
| SI (1) | SI2013166T1 (da) |
| UA (1) | UA96440C2 (da) |
| WO (1) | WO2007104780A2 (da) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2392915C1 (ru) * | 2009-04-14 | 2010-06-27 | Федеральное государственное учреждение "Новокузнецкий научно-практический центр медико-социальной экспертизы и реабилитации инвалидов Федерального агентства по здравоохранению и социальному развитию" (ФГУ ННПЦ МСЭ и РИ Росздрава) | Способ формирования двигательных функций у инвалидов с позвоночно-спинно-мозговой травмой |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LV14346B (lv) | 2009-11-05 | 2011-07-20 | Grindeks, A/S | 2-(4-Fenil-5-metil-2-oksopirolidin-1-il)-acetamīda 4R,5S-enantiomērs ar nootropo aktivitāti |
| RU2437659C1 (ru) * | 2010-11-12 | 2011-12-27 | Государственное образовательное учреждение высшего профессионального образования "Российский государственный педагогический университет им. А.И. Герцена" (РГПУ им. А.И. Герцена) | Средство, обладающее антидепрессивным, анксиолитическим и ноотропным действием |
| WO2012123358A1 (en) * | 2011-03-11 | 2012-09-20 | Grindeks | 4r,5r-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity |
| RU2480214C1 (ru) * | 2011-09-22 | 2013-04-27 | Валентина Ивановна Ахапкина | Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов |
| PL3517541T3 (pl) | 2012-05-08 | 2020-12-28 | Nicox Ophthalmics, Inc. | Postać polimorficzna propionianu flutykazonu |
| TW201408294A (zh) | 2012-07-05 | 2014-03-01 | Merz Pharma Gmbh & Co Kgaa | (r)-苯基披喇瑟盪於治療帕金森氏症之用除 |
| TW201408293A (zh) | 2012-07-05 | 2014-03-01 | Merz Pharma Gmbh & Co Kgaa | (r)-苯基披喇瑟盪於治療疾病相關疲勞之用途 |
| LV15003B (lv) * | 2013-10-22 | 2015-08-20 | Latvijas Organiskās Sintēzes Institūts | Farmaceitiska kompozīcija ķermeņa masas pieauguma kontrolei |
| LV15015B (lv) | 2013-12-13 | 2015-12-20 | Olainfarm, A/S | 3-karboksi-4-(R)-fenilpirolidin-2-ona sāls un tā pielietošana |
| LV15016B (lv) | 2013-12-18 | 2016-01-20 | Olainfarm, A/S | N-karbamoilmetil-4(R)-fenil-2-pirolidinona polimorfās formas |
| EP2891491A1 (en) | 2014-01-03 | 2015-07-08 | Merz Pharma GmbH & Co. KGaA | Use of (r)-phenylpiracetam for the treatment of sleep disorders |
| LV15072B (lv) | 2014-05-14 | 2016-09-20 | Olainfarm, A/S | Farmaceitiska kompozīcija izmantošanai patoloģiska stāvokļa, kam raksturīga paaugstināta iNOS gēna ekspresija, profilaksei un ārstēšanai |
| EP3127539A1 (en) * | 2015-08-03 | 2017-02-08 | Latvian Institute Of Organic Synthesis | Use of 2-(5s-methyl-2-oxo-4r-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures |
| JP2025529136A (ja) * | 2022-08-31 | 2025-09-04 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション | キラルガンマラクタム誘導体またはその薬学的に許容可能な塩およびその製造方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0004297D0 (en) * | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| RU2232578C1 (ru) * | 2003-04-10 | 2004-07-20 | Ахапкина Валентина Ивановна | Вещество, обладающее антидепрессивной активностью |
| RU2289404C1 (ru) * | 2005-04-06 | 2006-12-20 | ГОУ ВПО "Московский государственный медико-стоматологический университет Министерства здравоохранения РФ" | Способ премедикации у пациентов со средним уровнем психоэмоционального напряжения при амбулаторных стоматологических вмешательствах |
-
2006
- 2006-03-16 LV LVP-06-45A patent/LV13630B/en unknown
-
2007
- 2007-03-15 DE DE602007005244T patent/DE602007005244D1/de active Active
- 2007-03-15 EP EP07726915A patent/EP2013166B1/en active Active
- 2007-03-15 PL PL07726915T patent/PL2013166T3/pl unknown
- 2007-03-15 SI SI200730253T patent/SI2013166T1/sl unknown
- 2007-03-15 DK DK07726915.7T patent/DK2013166T3/da active
- 2007-03-15 PT PT07726915T patent/PT2013166E/pt unknown
- 2007-03-15 EA EA200801978A patent/EA014668B1/ru not_active IP Right Cessation
- 2007-03-15 GE GEAP200710934A patent/GEP20104915B/en unknown
- 2007-03-15 AT AT07726915T patent/ATE460396T1/de active
- 2007-03-15 EE EEP200800063A patent/EE05536B1/xx not_active IP Right Cessation
- 2007-03-15 ME MEP-2009-293A patent/ME01192B/me unknown
- 2007-03-15 CA CA2647206A patent/CA2647206C/en not_active Expired - Fee Related
- 2007-03-15 CN CNA2007800177832A patent/CN101448786A/zh active Pending
- 2007-03-15 UA UAA200812099A patent/UA96440C2/ru unknown
- 2007-03-15 WO PCT/EP2007/052424 patent/WO2007104780A2/en not_active Ceased
- 2007-03-15 US US12/226,332 patent/US9102615B2/en not_active Expired - Fee Related
- 2007-03-15 HR HRP20090524AA patent/HRP20090524C1/hr not_active IP Right Cessation
- 2007-03-15 ES ES07726915T patent/ES2342024T3/es active Active
-
2008
- 2008-09-22 LT LT2008075A patent/LT5589B/lt not_active IP Right Cessation
-
2010
- 2010-06-08 CY CY20101100506T patent/CY1110170T1/el unknown
-
2015
- 2015-04-16 US US14/688,633 patent/US9382203B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2392915C1 (ru) * | 2009-04-14 | 2010-06-27 | Федеральное государственное учреждение "Новокузнецкий научно-практический центр медико-социальной экспертизы и реабилитации инвалидов Федерального агентства по здравоохранению и социальному развитию" (ФГУ ННПЦ МСЭ и РИ Росздрава) | Способ формирования двигательных функций у инвалидов с позвоночно-спинно-мозговой травмой |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2013166B1 (en) | 2010-03-10 |
| GEP20104915B (en) | 2010-03-10 |
| CN101448786A (zh) | 2009-06-03 |
| LT5589B (lt) | 2009-08-25 |
| HRPK20090524B3 (hr) | 2012-12-31 |
| CA2647206A1 (en) | 2007-09-20 |
| UA96440C2 (ru) | 2011-11-10 |
| SI2013166T1 (sl) | 2010-07-30 |
| DE602007005244D1 (de) | 2010-04-22 |
| HRP20090524C1 (hr) | 2017-03-10 |
| PL2013166T3 (pl) | 2010-08-31 |
| US20150216846A1 (en) | 2015-08-06 |
| HRP20090524A2 (hr) | 2009-12-31 |
| ES2342024T3 (es) | 2010-06-30 |
| WO2007104780A3 (en) | 2007-11-29 |
| CA2647206C (en) | 2011-09-27 |
| US9382203B2 (en) | 2016-07-05 |
| LT2008075A (en) | 2009-06-25 |
| US20100022784A1 (en) | 2010-01-28 |
| ME01192B (me) | 2012-12-20 |
| EA200801978A1 (ru) | 2009-04-28 |
| WO2007104780A2 (en) | 2007-09-20 |
| DK2013166T3 (da) | 2010-07-05 |
| EA014668B1 (ru) | 2010-12-30 |
| ATE460396T1 (de) | 2010-03-15 |
| EE200800063A (et) | 2008-12-15 |
| EE05536B1 (et) | 2012-04-16 |
| CY1110170T1 (el) | 2015-01-14 |
| EP2013166A2 (en) | 2009-01-14 |
| PT2013166E (pt) | 2010-06-09 |
| US9102615B2 (en) | 2015-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2647206C (en) | N-carbamoylmethyl-4-(r)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use | |
| RU2140901C1 (ru) | АНАЛОГИ γ-АМИНОМАСЛЯНОЙ КИСЛОТЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ, СПОСОБ ЛЕЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ | |
| González-Sabı́n et al. | CAL-B-catalyzed resolution of some pharmacologically interesting β–substituted isopropylamines | |
| CN100383118C (zh) | 4-吡咯烷基-苯基-苄基醚衍生物 | |
| Baures et al. | Crystal structure, absolute configuration, and phosphodiesterase inhibitory activity of (+)-1-(4-bromobenzyl)-4-[(3-cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone | |
| US8957226B2 (en) | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | |
| GEP20043236B (en) | Asymmetric Synthesis of Pregabalin | |
| CA2702467A1 (en) | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | |
| IL160045A (en) | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacture of levetiracetam and analogues | |
| WO2023196614A1 (en) | Methods and compounds for treating neurological disorders | |
| ATE289583T1 (de) | Stereoisomere von propyl-isopropylacetamid, verfahren zu deren herstellung sowie diese enthaltende pharmazeutische zubereitungen | |
| Wang et al. | New synthesis of β-aryl-GABA drugs | |
| US20210355084A1 (en) | N-substituted indoles and use as allosteric modulators of cannabinoid receptors | |
| Sabala et al. | Asymmetric synthesis of α, β-substituted γ-amino acids via conjugate addition | |
| KR20070103497A (ko) | 모노아민 산화효소 ｂ 억제제로서의 순수한4-피롤리디노페닐벤질 에터 유도체의 제조 방법 | |
| JP4629105B2 (ja) | Ｍａｏｂインヒビターとしてのベンジルオキシ誘導体 | |
| HK1133005A (en) | N- carbamoylmethyl- 4- (r) -phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use | |
| WO2007104781A2 (en) | Method for manufacturing of r-enantiomer of n-carbamoylmethyl-4-phenyl-2-pyrrolidone | |
| Ai et al. | Chiral N-phosphonyl imine chemistry: asymmetric additions of glycine enolate to diphenyl diamine-based phosphonyl imines | |
| CA2780040C (en) | 4r,5s-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity | |
| RS20100352A2 (sr) | Metod pripreme i upotreba farmakološki aktivnog n-karbamilmetil-4(r)-fenil-2-pirolidinona | |
| Liu | An efficient synthesis of enantiomerically pure γ-aminobutyric acid (GABA) derivatives | |
| Ol’shevskaya et al. | Synthesis of carborane analogues of γ-aminobutanoic acid | |
| CN116162128A (zh) | 一种抗病毒感染的核苷衍生物及其制备方法与用途 | |
| KR100845366B1 (ko) | 모노아민 산화효소 ｂ 억제제로서 벤질옥시 유도체 |